Clinical Trials
MK-5684 vs. Abiraterone or Enzalutamide in prostate cancer patients
Disease Type: Prostate
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville